UCB SA (OTCMKTS:UCBJF) Given Consensus Recommendation of “Buy” by Brokerages

UCB SA (OTCMKTS:UCBJF) has received an average rating of “Buy” from the six research firms that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation.

A number of equities analysts recently issued reports on UCBJF shares. Barclays reiterated an “overweight” rating on shares of UCB in a research report on Tuesday, January 6th. Stephens reaffirmed an “overweight” rating on shares of UCB in a research note on Thursday, January 15th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a research note on Monday, December 8th. Wolfe Research began coverage on UCB in a research report on Monday. They issued an “outperform” rating for the company. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a report on Monday, February 16th.

UCB Stock Performance

UCBJF opened at $310.61 on Monday. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a twelve month low of $150.70 and a twelve month high of $345.39. The business’s 50 day moving average is $307.09 and its 200-day moving average is $280.05.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.